Baxter International Inc. (BAX)
NYSE: BAX · Real-Time Price · USD
19.07
-0.22 (-1.14%)
At close: Dec 18, 2025, 4:00 PM EST
18.99
-0.08 (-0.42%)
After-hours: Dec 18, 2025, 7:12 PM EST
Baxter International Revenue
Baxter International had revenue of $2.84B in the quarter ending September 30, 2025, with 5.04% growth. This brings the company's revenue in the last twelve months to $11.02B, up 3.90% year-over-year. In the year 2024, Baxter International had annual revenue of $10.64B with 2.66% growth.
Revenue (ttm)
$11.02B
Revenue Growth
+3.90%
P/S Ratio
0.89
Revenue / Employee
$290,079
Employees
38,000
Market Cap
9.80B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 10.64B | 276.00M | 2.66% |
| Dec 31, 2023 | 10.36B | 303.00M | 3.01% |
| Dec 31, 2022 | 10.06B | -2.09B | -17.20% |
| Dec 31, 2021 | 12.15B | 9.13B | 302.36% |
| Sep 30, 2021 | 3.02B | -8.65B | -74.14% |
| Dec 31, 2020 | 11.67B | 8.79B | 305.17% |
| Sep 30, 2020 | 2.88B | -8.48B | -74.64% |
| Dec 31, 2019 | 11.36B | 263.00M | 2.37% |
| Dec 31, 2018 | 11.10B | 538.00M | 5.09% |
| Dec 31, 2017 | 10.56B | 398.00M | 3.92% |
| Dec 31, 2016 | 10.16B | 195.00M | 1.96% |
| Dec 31, 2015 | 9.97B | -751.00M | -7.01% |
| Dec 31, 2014 | 10.72B | 1.31B | 13.87% |
| Dec 31, 2013 | 9.41B | -4.52B | -32.46% |
| Dec 31, 2012 | 13.94B | 43.00M | 0.31% |
| Dec 31, 2011 | 13.89B | 1.05B | 8.18% |
| Dec 31, 2010 | 12.84B | 281.00M | 2.24% |
| Dec 31, 2009 | 12.56B | 214.00M | 1.73% |
| Dec 31, 2008 | 12.35B | 1.09B | 9.63% |
| Dec 31, 2007 | 11.26B | 885.00M | 8.53% |
| Dec 31, 2006 | 10.38B | 529.00M | 5.37% |
| Dec 31, 2005 | 9.85B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
BAX News
- 2 days ago - Bragar Eagel & Squire is Investigating Certain Officers and Directors of Baxter International and Molina Healthcare on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - GlobeNewsWire
- 6 days ago - DOC HOLLYWOOD: A Psychiatrist Takes 3rd Place with Baxter's Brain at the American Film Market Pitch Conference - GlobeNewsWire
- 7 days ago - INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Baxter International - GlobeNewsWire
- 7 days ago - Baxter Presents Real-World Data at American Society of Health System Pharmacists Meeting Demonstrating Smart Infusion Pump Electronic Medical Record (EMR) Integration May Improve Patient Safety and Nursing Bedside Productivity - Business Wire
- 8 days ago - Scrooge: 5 Stocks That Could Ruin Your Santa Rally - Seeking Alpha
- 10 days ago - BAX INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Baxter International - Newsfile Corp
- 11 days ago - Macquarie Value Fund Q3 2025 Sales And Purchases - Seeking Alpha
- 14 days ago - Bragar Eagel & Squire, P.C. Reminds James Hardie and Baxter International Investors to Contact the Firm Regarding Their Rights - GlobeNewsWire